Pleasanton
PLEASANTON, California, December 16, 2011 -
- The test confidently detects HLA-B*5701 to help decrease risk of abacavir hypersensitivity reaction
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its HLA-B*5701 screening test[1] is now commercially available in Europe.
PLEASANTON, California, October 12, 2011 -
CooperVision, Inc.
PLEASANTON, California, August 23, 2011 -
- cobas BRAF Mutation Test is used to identify patients with melanoma tumors that harbor a genetic mutation which can be treated with Zelboraf (vemurafenib)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas BRAF Mutation Test is now commercially available in Europe and in countries that recognize the CE mark.
PLEASANTON, California, July 22, 2011 -
- cobas KRAS
Mutation Test identifies colorectal cancer patients not likely to
respond to anti-EGFR antibody therapies.
PLEASANTON, California, May 23, 2011 -
- cobas(R) TaqScreen MPX Test, v2.0(1) provides real-time results for
HIV, HCV and HBV
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas(R)
TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now
commercially available in Europe.
More News
- Test with enhanced reliability for monitoring HIV patients now CE marked
- Test measures viral load of potentially deadly virus for transplant patients
- New Veeva iRep Application Satisfies the Pharmaceutical Industry's Appetite for the Fastest Growing Computing Device in History
- QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital(TM) PCR Platform and Establish Commercial Operations by 2011
- Collaboration is based on recent DKFZ discovery suggesting cervical cancer risk may be more precisely determined
- cobas(R) TaqScreen DPX Test offers real-time discrimination in a single assay(1)
- cobas(R) TaqScreen DPX Test offers real-time discrimination in a single assay(1)
- Roche Obtains Co-Exclusive License to Develop PCR Assays Detecting Mutations in the PI3K Oncogene
- Easy-to-use molecular test offers faster results to help healthcare facilities control spread of methicillin-resistant Staphylococcus aureus (MRSA)
- First dual-PCR target viral load test approved for monitoring HIV patients receiving antiretroviral therapy
- CooperVision Adds Global Professional Relations Role; Richard Clompus Joins Company as Vice President
- New cobas(R) 4800 System designed to increase laboratory efficiency and medical value
- cobas(R) TaqScreen MPX Test is the most comprehensive - detects multiple viruses for increased plasma product safety
- STUDY SHOWS TWO-YEAR SURVIVAL OF 58 PERCENT AND DRAMATIC IMPROVEMENT IN QUALITY OF LIFE FOR HEARTMATE II PATIENTS
- Roche Introduces New cobas p 630 Instrument and AMPLILINK 3.3 Series Software With CE Mark
- Trapeze Networks Announces World’s First Centrally-Managed Enterprise-Class 802.11n Outdoor AP
- Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
- Best Vienna Hotel Selects Best NonStop Wi-Fi Network
- Beijing Science Park Selects Trapeze Networks for Building Campus-Wide Wi-Fi Network
- Largest Interdisciplinary Research Center in Europe Implements Trapeze Networks’ NonStop Wireless Networking
- Trapeze Networks: Working to Raise the Bar on Customer Satisfaction
- 802.11n Finalization Feeding Frenzy Fascinating Folks From Fairbanks to Florida
- Trapeze Networks and TESSCO Technologies Announce Distribution Alliance
- Trapeze Networks’ Matthew Gast Reports 802.11n Approaching Final Approval
- Trapeze Networks Awarded Two More Breakthrough Patents
- Trapeze Networks RF Firewall: Location-Based WLAN Security
- Demand for Location Services Driving Trapeze Networks to Deliver High Capacity Solutions
- Trapeze Networks Introduces New 802.11n Access Point Meeting Unique Demands of High-Density Deployments
- Trapeze Networks: WLAN Leader at Trusted Network Connect Standards Test
- Trapeze Networks Announces Newbury Active Asset 4.0, WLAN Asset Tracking and Management
